The UK meningitis outbreak and ME/CFS: why patients with immune dysfunction should pay attention
Two people are dead and twenty cases have been reported in a meningococcal group B outbreak centered on Canterbury, Kent. The outbreak is linked to a nightclub and the University of Kent, and UKHSA is deploying antibiotics and targeted Bexsero vaccination to contain it.
For the general public in continental Europe, this is not yet cause for alarm. But if you have ME/CFS — or care for someone who does — the biology of this situation deserves a closer look.
1 ME/CFS patients have documented immune dysfunction
The immune vulnerabilities here are well-established in peer-reviewed literature, not theoretical. Start with NK cells — natural killer cells, part of the innate immune system’s rapid-response arsenal. In ME/CFS, NK cell cytotoxicity is consistently reduced, one of the most replicated findings in the field, documented since Caligiuri et al. in 1987 (Caligiuri et al. 1987) and confirmed across dozens of studies since; these cells contribute to early pathogen containment through cytokine-mediated activation of macrophages and neutrophils. Then there’s T cell exhaustion: a landmark 2024 study from the Hanson lab at Cornell (Iu et al., PNAS) (Iu et al. 2024) demonstrated that CD8+ T cells in ME/CFS patients show epigenetic reprogramming toward exhaustion — elevated SLAMF6, SLAMF7, EOMES, and TOX markers — which is not transient activation fatigue but a programmed state that durably reduces the adaptive immune system’s capacity to fight infections. Finally, complement consumption: ME/CFS patients show ongoing complement activation — Sorensen et al. (2003) (Sorensen et al. 2003) found elevated C4a split products indicating classical pathway consumption, and Glass et al. (2025) (Glass et al. 2025) confirmed broader complement dysregulation post-exercise. Terminal complement deficiency is the single strongest individual risk factor for recurrent invasive meningococcal disease. The ME/CFS complement phenotype isn’t genetic terminal deficiency, but ongoing consumption of complement components is not normal either, and any reduction in complement availability matters for a pathogen that complement is critical for clearing.
2 The blood-brain barrier problem
Here’s where it gets specific to meningitis.
Meningitis works by crossing the blood-brain barrier (BBB) to infect the brain and its surrounding membranes — the entire disease depends on breaching this structure (Piñas et al. 2022). ME/CFS patients show evidence that their BBB is already under strain: elevated CSF/serum albumin ratios indicating increased permeability, peripheral inflammatory markers appearing in cerebrospinal fluid, and ongoing neuroinflammation with microglial activation (Gottschalk et al. 2022). Meningeal mast cells, recently implicated in regulating CSF dynamics, may further amplify this vulnerability (Christodoulides et al. 2025).
This creates what I call a “double vulnerability”: a pathogen that specifically attacks a structure already weakened by the underlying disease. The bacteria may have an easier route in, and the immune system may be slower to stop them.
3 Meningitis can trigger or worsen ME/CFS
The risk isn’t just the acute infection. Two recent studies found that 31–34% of meningitis survivors report persistent fatigue at follow-up, independent of how severe the acute illness was (Schwitter 2024 (Schwitter et al. 2024), Ungureanu 2021 (Ungureanu et al. 2021)); an earlier study (Hotopf et al., 1996 (Hotopf, Noah, and Wessely 1996)) similarly documented chronic fatigue following viral meningitis. More strikingly, Ungureanu et al. (Ungureanu et al. 2021) found that 53% of post-meningitis patients reported “rapid exhaustion after cognitive effort” — a symptom that overlaps significantly with the cognitive component of post-exertional malaise, the hallmark of ME/CFS.
For someone who already has ME/CFS, a severe infection like meningitis represents a major risk of permanent functional decline. The “infection ratchet” model — consistent with Q Fever Fatigue Syndrome data showing 98.9% of patients still experiencing PEM after 10 years (Spronk et al., 2023 (Spronk et al. 2023)), and with the broader pattern of post-infectious fatigue syndromes being durable once established — suggests that each significant infection risks a step-wise, potentially irreversible drop in baseline functioning.
4 The good news: vaccination is safe and effective for ME/CFS patients
Population-level data from Norway (Magnus et al., 2015 (Magnus et al. 2015)) showed that actual influenza infection doubled the risk of developing ME/CFS (hazard ratio: 2.04), while the adjuvanted pandemic vaccine showed zero increased risk (hazard ratio: 0.97). A separate Norwegian study (Magnus et al., 2009 (Magnus et al. 2009)) found no association between an earlier meningococcal B OMV vaccine (MenBvac, not Bexsero) and ME (adjusted OR: 1.06). The only study directly measuring vaccine immunogenicity in ME patients (Prinsen et al., 2012 (Prinsen et al. 2012)) found that patients mounted antibody responses identical to healthy controls.
Put differently: vaccination protects against the thing that triggers disease worsening, without itself adding any risk. For ME/CFS patients, that asymmetry is the crux of the matter.
5 A complication: what COVID may have done to your immune memory
There’s been a lot of discussion about whether COVID-19 “resets” the immune system — whether a SARS-CoV-2 infection can wipe out immunity you built up through earlier vaccinations or infections, the way measles famously does. The picture that’s emerging from the research is more nuanced than the headlines suggest, and it matters here.
The reassuring part first: COVID does not appear to cause measles-like immune amnesia. Studies tracking pre-existing antibodies against diphtheria, tetanus, and pertussis found that titres remained stable after COVID-19 infection. Your childhood vaccines, in other words, probably still work.
But COVID does cause measurable immune damage through other mechanisms. Persistent lymphopenia — chronically low lymphocyte counts — affects 7–12% of people who had moderate-to-severe COVID (Phetsouphanh et al., 2022 (Phetsouphanh et al. 2022)). T cell exhaustion markers (PD-1, TIM-3, CTLA-4) remain elevated long after the acute infection resolves, and a 190-participant study found that Long COVID and ME/CFS patients had comparable immune profiles: lower lymphocytes, lower CD8+ T cells, lower NK cells, and higher inflammatory cytokines (Rohrhofer et al., 2024 (Rohrhofer et al. 2024)). Persistent complement dysregulation — ongoing consumption of complement components — has been confirmed in Long COVID patients by a 2024 Science paper (Klein et al. (Klein et al. 2024)).
What does this mean for vaccine protection going forward? Nobody has studied that directly in ME/CFS patients, and that’s a significant gap. But here’s the concern: if you already had ME/CFS immune dysfunction — reduced NK cells, exhausted T cells, complement consumption — and then COVID layered additional immune damage on top of that, you may not respond to new vaccinations as well as the Prinsen 2012 study (which predates COVID by a decade) would predict. Whether ME/CFS patients who went through COVID need additional booster doses, or should have their antibody titres monitored after vaccination, are questions that don’t have answers yet but probably should.
6 What does Bexsero actually cover?
Bexsero (4CMenB) is the vaccine being deployed in Kent. It targets four antigens on the meningococcal B surface: fHbp, NHBA, NadA, and PorA. Real-world UK data show 83% effectiveness against any MenB strain, and 94% against strains predicted to be vaccine-preventable (Ladhani et al. 2020 (Ladhani et al. 2020), GSK data); since the NHS infant programme began in 2015, MenB cases in vaccine-eligible children have dropped 75%.
However — and this matters — Bexsero doesn’t cover all MenB strains equally. Coverage varies by clonal complex: excellent for cc41/44 (~94%) and cc32 (~96%), but declining for cc269 (down to 53%). The specific clonal complex of the Kent outbreak strain hasn’t yet been publicly identified, and Prof Andrew Pollard (Oxford) has noted that “the first question on vaccination is whether this B strain is covered by the vaccine, as this isn’t always the case.” A second MenB vaccine, Trumenba (Pfizer), has higher predicted MenB-specific coverage (90% vs 67%) due to targeting two fHbp subfamilies; it’s licensed but not in the routine UK or Belgian programmes.
7 What ME/CFS patients should consider doing
None of what follows is medical advice — these are evidence-based considerations to raise with your doctor, and they’re worth raising.
If you were born before 2015 in the UK, or are an adult anywhere in Europe, you almost certainly haven’t been vaccinated against MenB; MenACWY may be in your history depending on your country’s schedule. In Belgium, Bexsero is available by prescription (~€80–90 per dose, two doses needed), and ME/CFS patients with documented complement consumption or other immune dysfunction could discuss with their physician whether they meet the criteria for at-risk groups under Belgian Superior Health Council guidelines (which cover complement deficiency and asplenia). Timing matters if you pursue this: don’t get vaccinated during a crash or flare, and plan for 3–5 days of rest after each dose, since Bexsero tends to be more reactogenic than MenACWY vaccines.
Beyond vaccination, basic infection prevention — hand hygiene, not sharing drinks or utensils, avoiding prolonged close contact in crowded enclosed spaces — is genuine disease-modifying behaviour for ME/CFS patients, not overcaution. Every infection you prevent is a step-wise decline you avoid. And if you’re travelling to the Canterbury/Kent area, it’s worth a conversation with your GP about pre-travel vaccination; the outbreak is currently geographically contained, but close-contact settings like nightclubs and dormitories are high-risk environments.
8 The broader picture
What makes ME/CFS so difficult to live with is precisely this: the immune dysfunction underlying the disease also makes every subsequent infection more dangerous and more likely to produce permanent worsening. Every outbreak — COVID, influenza, meningitis — carries disproportionate risk for this population, and the research is unambiguous that infection triggers disease onset and progression while vaccination does not. For ME/CFS patients, that asymmetry should inform every decision about infection risk.